Seven-year surveillance of emm types of pediatric Group A streptococcal pharyngitis isolates in Western Greece

An experimental 26-valent M protein Group A streptococcal (GAS) vaccine has entered clinical studies. Pharyngeal GAS emm type surveillances in different areas and time-periods enhance the understanding of the epidemiology of GAS pharyngitis. Moreover, these surveillances, combined with the data on G...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 8; no. 8; p. e71558
Main Authors Syrogiannopoulos, George A, Grivea, Ioanna N, Al-Lahham, Adnan, Panagiotou, Maria, Tsantouli, Alexandra G, Michoula Ralf René Reinert, Aspasia N, van der Linden, Mark
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 19.08.2013
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
Abstract An experimental 26-valent M protein Group A streptococcal (GAS) vaccine has entered clinical studies. Pharyngeal GAS emm type surveillances in different areas and time-periods enhance the understanding of the epidemiology of GAS pharyngitis. Moreover, these surveillances, combined with the data on GAS invasive disease, can play a significant role in the formulation of multivalent type-specific vaccines. During a 7-year period (1999-2005), 2408 GAS isolates were recovered from consecutive children with pharyngitis in Western Greece. The overall macrolide resistance rate was 22.8%. Along the study period we noted a tendency towards significantly decreased rates of resistance, with the lowest rates occurring in 2002 (15.3%), 2003 (15%) and 2004 (16.7%). A random sample of isolates from each year, 338 (61.7%) of the 548 macrolide-resistant and 205 (11%) of the macrolide-susceptible, underwent molecular analysis, including emm typing. The 543 typed isolates had 28 different emm types. A statistically significant association was found between macrolide resistance and emm4, emm22 and emm77, whereas emm1, emm3, emm6, emm12, emm87 and emm89 were associated with macrolide susceptibility. A significant yearly fluctuation was observed in emm4, emm28 and emm77. The most common macrolide-resistant GAS were emm77 isolates harboring erm(A), either alone or in combination with mef(A), emm4 carrying mef(A), emm28 possessing erm(B), emm75 carrying mef(A), emm12 harboring mef(A) and emm22 carrying erm(A). We estimated that 82.8% of the isolates belonged to emm types included in the novel 26-valent M protein vaccine. The vaccine coverage rate was determined mainly by the increased frequency of nonvaccine emm4 isolates. A limited number of emm types dominated among macrolide-susceptible and macrolide-resistant GAS isolates. We observed seasonal fluctuations, which were significant for emm4, emm28 and emm77. This type of data can serve as baseline information if the novel 26-valent M protein GAS vaccine is introduced into practice.
AbstractList An experimental 26-valent M protein Group A streptococcal (GAS) vaccine has entered clinical studies. Pharyngeal GAS emm type surveillances in different areas and time-periods enhance the understanding of the epidemiology of GAS pharyngitis. Moreover, these surveillances, combined with the data on GAS invasive disease, can play a significant role in the formulation of multivalent type-specific vaccines. During a 7-year period (1999-2005), 2408 GAS isolates were recovered from consecutive children with pharyngitis in Western Greece. The overall macrolide resistance rate was 22.8%. Along the study period we noted a tendency towards significantly decreased rates of resistance, with the lowest rates occurring in 2002 (15.3%), 2003 (15%) and 2004 (16.7%). A random sample of isolates from each year, 338 (61.7%) of the 548 macrolide-resistant and 205 (11%) of the macrolide-susceptible, underwent molecular analysis, including emm typing. The 543 typed isolates had 28 different emm types. A statistically significant association was found between macrolide resistance and emm4, emm22 and emm77, whereas emm1, emm3, emm6, emm12, emm87 and emm89 were associated with macrolide susceptibility. A significant yearly fluctuation was observed in emm4, emm28 and emm77. The most common macrolide-resistant GAS were emm77 isolates harboring erm(A), either alone or in combination with mef(A), emm4 carrying mef(A), emm28 possessing erm(B), emm75 carrying mef(A), emm12 harboring mef(A) and emm22 carrying erm(A). We estimated that 82.8% of the isolates belonged to emm types included in the novel 26-valent M protein vaccine. The vaccine coverage rate was determined mainly by the increased frequency of nonvaccine emm4 isolates. A limited number of emm types dominated among macrolide-susceptible and macrolide-resistant GAS isolates. We observed seasonal fluctuations, which were significant for emm4, emm28 and emm77. This type of data can serve as baseline information if the novel 26-valent M protein GAS vaccine is introduced into practice.
An experimental 26-valent M protein Group A streptococcal (GAS) vaccine has entered clinical studies. Pharyngeal GAS emm type surveillances in different areas and time-periods enhance the understanding of the epidemiology of GAS pharyngitis. Moreover, these surveillances, combined with the data on GAS invasive disease, can play a significant role in the formulation of multivalent type-specific vaccines. During a 7-year period (1999-2005), 2408 GAS isolates were recovered from consecutive children with pharyngitis in Western Greece. The overall macrolide resistance rate was 22.8%. Along the study period we noted a tendency towards significantly decreased rates of resistance, with the lowest rates occurring in 2002 (15.3%), 2003 (15%) and 2004 (16.7%). A random sample of isolates from each year, 338 (61.7%) of the 548 macrolide-resistant and 205 (11%) of the macrolide-susceptible, underwent molecular analysis, including emm typing. The 543 typed isolates had 28 different emm types. A statistically significant association was found between macrolide resistance and emm4, emm22 and emm77, whereas emm1, emm3, emm6, emm12, emm87 and emm89 were associated with macrolide susceptibility. A significant yearly fluctuation was observed in emm4, emm28 and emm77. The most common macrolide-resistant GAS were emm77 isolates harboring erm(A), either alone or in combination with mef(A), emm4 carrying mef(A), emm28 possessing erm(B), emm75 carrying mef(A), emm12 harboring mef(A) and emm22 carrying erm(A). We estimated that 82.8% of the isolates belonged to emm types included in the novel 26-valent M protein vaccine. The vaccine coverage rate was determined mainly by the increased frequency of nonvaccine emm4 isolates. A limited number of emm types dominated among macrolide-susceptible and macrolide-resistant GAS isolates. We observed seasonal fluctuations, which were significant for emm4, emm28 and emm77. This type of data can serve as baseline information if the novel 26-valent M protein GAS vaccine is introduced into practice.
BACKGROUND: An experimental 26-valent M protein Group A streptococcal (GAS) vaccine has entered clinical studies. Pharyngeal GAS emm type surveillances in different areas and time-periods enhance the understanding of the epidemiology of GAS pharyngitis. Moreover, these surveillances, combined with the data on GAS invasive disease, can play a significant role in the formulation of multivalent type-specific vaccines. METHODS: During a 7-year period (1999-2005), 2408 GAS isolates were recovered from consecutive children with pharyngitis in Western Greece. The overall macrolide resistance rate was 22.8%. Along the study period we noted a tendency towards significantly decreased rates of resistance, with the lowest rates occurring in 2002 (15.3%), 2003 (15%) and 2004 (16.7%). A random sample of isolates from each year, 338 (61.7%) of the 548 macrolide-resistant and 205 (11%) of the macrolide-susceptible, underwent molecular analysis, including emm typing. RESULTS: The 543 typed isolates had 28 different emm types. A statistically significant association was found between macrolide resistance and emm4, emm22 and emm77, whereas emm1, emm3, emm6, emm12, emm87 and emm89 were associated with macrolide susceptibility. A significant yearly fluctuation was observed in emm4, emm28 and emm77. The most common macrolide-resistant GAS were emm77 isolates harboring erm(A), either alone or in combination with mef(A), emm4 carrying mef(A), emm28 possessing erm(B), emm75 carrying mef(A), emm12 harboring mef(A) and emm22 carrying erm(A). We estimated that 82.8% of the isolates belonged to emm types included in the novel 26-valent M protein vaccine. The vaccine coverage rate was determined mainly by the increased frequency of nonvaccine emm4 isolates. CONCLUSIONS: A limited number of emm types dominated among macrolide-susceptible and macrolide-resistant GAS isolates. We observed seasonal fluctuations, which were significant for emm4, emm28 and emm77. This type of data can serve as baseline information if the novel 26-valent M protein GAS vaccine is introduced into practice.
BACKGROUNDAn experimental 26-valent M protein Group A streptococcal (GAS) vaccine has entered clinical studies. Pharyngeal GAS emm type surveillances in different areas and time-periods enhance the understanding of the epidemiology of GAS pharyngitis. Moreover, these surveillances, combined with the data on GAS invasive disease, can play a significant role in the formulation of multivalent type-specific vaccines. METHODSDuring a 7-year period (1999-2005), 2408 GAS isolates were recovered from consecutive children with pharyngitis in Western Greece. The overall macrolide resistance rate was 22.8%. Along the study period we noted a tendency towards significantly decreased rates of resistance, with the lowest rates occurring in 2002 (15.3%), 2003 (15%) and 2004 (16.7%). A random sample of isolates from each year, 338 (61.7%) of the 548 macrolide-resistant and 205 (11%) of the macrolide-susceptible, underwent molecular analysis, including emm typing. RESULTSThe 543 typed isolates had 28 different emm types. A statistically significant association was found between macrolide resistance and emm4, emm22 and emm77, whereas emm1, emm3, emm6, emm12, emm87 and emm89 were associated with macrolide susceptibility. A significant yearly fluctuation was observed in emm4, emm28 and emm77. The most common macrolide-resistant GAS were emm77 isolates harboring erm(A), either alone or in combination with mef(A), emm4 carrying mef(A), emm28 possessing erm(B), emm75 carrying mef(A), emm12 harboring mef(A) and emm22 carrying erm(A). We estimated that 82.8% of the isolates belonged to emm types included in the novel 26-valent M protein vaccine. The vaccine coverage rate was determined mainly by the increased frequency of nonvaccine emm4 isolates. CONCLUSIONSA limited number of emm types dominated among macrolide-susceptible and macrolide-resistant GAS isolates. We observed seasonal fluctuations, which were significant for emm4, emm28 and emm77. This type of data can serve as baseline information if the novel 26-valent M protein GAS vaccine is introduced into practice.
Background An experimental 26-valent M protein Group A streptococcal (GAS) vaccine has entered clinical studies. Pharyngeal GAS emm type surveillances in different areas and time-periods enhance the understanding of the epidemiology of GAS pharyngitis. Moreover, these surveillances, combined with the data on GAS invasive disease, can play a significant role in the formulation of multivalent type-specific vaccines. Methods During a 7-year period (1999–2005), 2408 GAS isolates were recovered from consecutive children with pharyngitis in Western Greece. The overall macrolide resistance rate was 22.8%. Along the study period we noted a tendency towards significantly decreased rates of resistance, with the lowest rates occurring in 2002 (15.3%), 2003 (15%) and 2004 (16.7%). A random sample of isolates from each year, 338 (61.7%) of the 548 macrolide-resistant and 205 (11%) of the macrolide-susceptible, underwent molecular analysis, including emm typing. Results The 543 typed isolates had 28 different emm types. A statistically significant association was found between macrolide resistance and emm4, emm22 and emm77, whereas emm1, emm3, emm6, emm12, emm87 and emm89 were associated with macrolide susceptibility. A significant yearly fluctuation was observed in emm4, emm28 and emm77. The most common macrolide-resistant GAS were emm77 isolates harboring erm(A), either alone or in combination with mef(A), emm4 carrying mef(A), emm28 possessing erm(B), emm75 carrying mef(A), emm12 harboring mef(A) and emm22 carrying erm(A). We estimated that 82.8% of the isolates belonged to emm types included in the novel 26-valent M protein vaccine. The vaccine coverage rate was determined mainly by the increased frequency of nonvaccine emm4 isolates. Conclusions A limited number of emm types dominated among macrolide-susceptible and macrolide-resistant GAS isolates. We observed seasonal fluctuations, which were significant for emm4, emm28 and emm77. This type of data can serve as baseline information if the novel 26-valent M protein GAS vaccine is introduced into practice.
Audience Academic
Author Tsantouli, Alexandra G
van der Linden, Mark
Al-Lahham, Adnan
Syrogiannopoulos, George A
Michoula Ralf René Reinert, Aspasia N
Grivea, Ioanna N
Panagiotou, Maria
AuthorAffiliation 4 University of Patras, School of Health Sciences, Faculty of Medicine, General University Hospital of Patras, Rion, Patras, Greece
1 University of Thessaly, School of Health Sciences, Faculty of Medicine, General University Hospital of Larissa, Biopolis, Larissa, Greece
2 Institute for Medical Microbiology and National Reference Center for Streptococci, University Hospital, Aachen, Germany
Rockefeller University, United States of America
3 School of Applied Medical Sciences, German Jordanian University, Amman, Jordan
AuthorAffiliation_xml – name: 1 University of Thessaly, School of Health Sciences, Faculty of Medicine, General University Hospital of Larissa, Biopolis, Larissa, Greece
– name: 4 University of Patras, School of Health Sciences, Faculty of Medicine, General University Hospital of Patras, Rion, Patras, Greece
– name: Rockefeller University, United States of America
– name: 2 Institute for Medical Microbiology and National Reference Center for Streptococci, University Hospital, Aachen, Germany
– name: 3 School of Applied Medical Sciences, German Jordanian University, Amman, Jordan
Author_xml – sequence: 1
  givenname: George A
  surname: Syrogiannopoulos
  fullname: Syrogiannopoulos, George A
  organization: University of Thessaly, School of Health Sciences, Faculty of Medicine, General University Hospital of Larissa, Biopolis, Larissa, Greece
– sequence: 2
  givenname: Ioanna N
  surname: Grivea
  fullname: Grivea, Ioanna N
– sequence: 3
  givenname: Adnan
  surname: Al-Lahham
  fullname: Al-Lahham, Adnan
– sequence: 4
  givenname: Maria
  surname: Panagiotou
  fullname: Panagiotou, Maria
– sequence: 5
  givenname: Alexandra G
  surname: Tsantouli
  fullname: Tsantouli, Alexandra G
– sequence: 6
  givenname: Aspasia N
  surname: Michoula Ralf René Reinert
  fullname: Michoula Ralf René Reinert, Aspasia N
– sequence: 7
  givenname: Mark
  surname: van der Linden
  fullname: van der Linden, Mark
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23977078$$D View this record in MEDLINE/PubMed
BookMark eNqNk11r2zAUhs3oWD-2fzA2w2BsF8lkSbbsm0EoWxcoFNZ9XApZOk4UHMmV5LD8-8mNW-LRi9lgW_LzvjrnSOc8OTHWQJK8ztA8Iyz7tLG9M6Kdd3F6jhDL8rx8lpxlFcGzAiNycvR9mpx7v0EoJ2VRvEhOMakYQ6w8S8wt7MDM9iBc6nu3A922wkhIbZPCdpuGfQd-GHSgtAhOy_TK2b5LF6kPDrpgpZVStGm3Fm5vVjpon2pvWxGiTpv0N_gAzkQVgISXyfNGtB5eje-L5OfXLz8uv82ub66Wl4vrmSwqHGYMKVKUOG9qIiHDRc3U_QgrARTTGuJFGyVFXRBAtVC1Ugo1ijKalYAbcpG8Pfh2rfV8LJXnGSUxa1ZgFonlgVBWbHjn9DbGz63Q_H7CuhUXLmjZAkekzCSoGhpcU1xRkStZFUVDakILSVX0-jyu1tdbUBJMcKKdmE7_GL3mK7vjhFGGMxQNPowGzt71sWJ8q72EYSvA9kPcuMQsPoe43_2DPp3dSK1ETECbxsZ15WDKF5SVOMtxVURq_gQVbwVbLeO5anScnwg-TgSRCfAnrETvPV_efv9_9ubXlH1_xK5BtGEdz1AftDV-CtIDKJ313kHzWOQM8aEtHqrBh7bgY1tE2ZvjDXoUPfQB-QtOHAyW
CitedBy_id crossref_primary_10_1093_jac_dkw116
crossref_primary_10_1089_mdr_2015_0040
crossref_primary_10_1099_jmm_0_001158
crossref_primary_10_1128_mBio_01378_15
crossref_primary_10_1080_14787210_2017_1358612
crossref_primary_10_1016_j_autrev_2015_03_001
crossref_primary_10_1007_s10096_016_2704_y
crossref_primary_10_1128_JCM_00301_15
crossref_primary_10_5812_pedinfect_111172
crossref_primary_10_1371_journal_pone_0232777
crossref_primary_10_1016_j_jiac_2016_06_013
crossref_primary_10_7883_yoken_JJID_2023_332
crossref_primary_10_1089_mdr_2016_0129
crossref_primary_10_1586_14787210_2015_1023292
Cites_doi 10.1128/JCM.34.4.953-958.1996
10.1016/S1473-3099(03)00576-0
10.1016/j.diagmicrobio.2007.10.020
10.1086/426025
10.1097/01.inf.0000138080.74674.a2
10.1097/01.inf.0000190023.89759.96
10.1128/JCM.41.6.2385-2390.2003
10.1016/j.vaccine.2011.09.005
10.1084/jem.163.5.1191
10.1007/s10096-004-1274-6
10.1016/S0264-410X(98)00150-9
10.1128/AAC.46.12.3987-3990.2002
10.1128/JCM.02155-08
10.1016/0264-410X(96)00050-3
10.1086/521263
10.1179/joc.2007.19.5.500
10.1016/j.diagmicrobio.2009.03.004
10.1093/jac/dkq006
10.1128/AAC.01133-12
10.1111/j.1469-0691.2008.02104.x
10.1099/jmm.0.46481-0
10.1128/IAI.70.4.2171-2177.2002
10.1086/444458
10.1128/JCM.41.3.1307-1310.2003
10.1016/S1473-3099(09)70178-1
10.1016/j.ijantimicag.2010.01.025
10.1084/jem.161.3.623
10.1086/521264
10.1038/292457a0
10.1128/AAC.48.9.3559-3562.2004
10.1128/AAC.50.1.256-261.2006
10.1086/599344
10.1007/s00431-008-0819-6
10.1128/AAC.49.5.2109-2111.2005
10.3201/eid1809.120049
10.1086/519936
10.4049/jimmunol.89.3.307
10.1089/10766290152045039
10.1007/BF00215250
10.3201/eid/1706.100804
10.1186/1471-2180-12-215
10.1128/AAC.43.8.1935
10.1097/00001648-199001000-00010
ContentType Journal Article
Copyright COPYRIGHT 2013 Public Library of Science
2013 Syrogiannopoulos et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2013 Syrogiannopoulos et al 2013 Syrogiannopoulos et al
Copyright_xml – notice: COPYRIGHT 2013 Public Library of Science
– notice: 2013 Syrogiannopoulos et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2013 Syrogiannopoulos et al 2013 Syrogiannopoulos et al
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
IOV
ISR
3V.
7QG
7QL
7QO
7RV
7SN
7SS
7T5
7TG
7TM
7U9
7X2
7X7
7XB
88E
8AO
8C1
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
ABJCF
ABUWG
AFKRA
ARAPS
ATCPS
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
C1K
CCPQU
D1I
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
KB.
KB0
KL.
L6V
LK8
M0K
M0S
M1P
M7N
M7P
M7S
NAPCQ
P5Z
P62
P64
PATMY
PDBOC
PIMPY
PQEST
PQQKQ
PQUKI
PTHSS
PYCSY
RC3
7X8
5PM
DOA
DOI 10.1371/journal.pone.0071558
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Opposing Viewpoints Resource Center
Gale In Context: Science
ProQuest Central (Corporate)
Animal Behavior Abstracts
Bacteriology Abstracts (Microbiology B)
Biotechnology Research Abstracts
ProQuest Nursing & Allied Health Database
Ecology Abstracts
Entomology Abstracts (Full archive)
Immunology Abstracts
Meteorological & Geoastrophysical Abstracts
Nucleic Acids Abstracts
Virology and AIDS Abstracts
Agricultural Science Collection
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
ProQuest Public Health Database
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Materials Science & Engineering Collection
ProQuest Central (Alumni)
ProQuest Central
Advanced Technologies & Aerospace Database‎ (1962 - current)
ProQuest Agriculture & Environmental Science Database
ProQuest Central Essentials
Biological Science Collection
AUTh Library subscriptions: ProQuest Central
Technology Collection
ProQuest Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Materials Science Collection
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
https://resources.nclive.org/materials
Nursing & Allied Health Database (Alumni Edition)
Meteorological & Geoastrophysical Abstracts - Academic
ProQuest Engineering Collection
Biological Sciences
Agricultural Science Database
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
ProQuest Engineering Database
Nursing & Allied Health Premium
ProQuest Advanced Technologies & Aerospace Database
ProQuest Advanced Technologies & Aerospace Collection
Biotechnology and BioEngineering Abstracts
Environmental Science Database
Materials Science Collection
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
Engineering Collection
Environmental Science Collection
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Agricultural Science Database
Publicly Available Content Database
ProQuest Central Student
ProQuest Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
Environmental Sciences and Pollution Management
Health Research Premium Collection
Meteorological & Geoastrophysical Abstracts
Natural Science Collection
Biological Science Collection
ProQuest Medical Library (Alumni)
Engineering Collection
Advanced Technologies & Aerospace Collection
Engineering Database
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Agricultural Science Collection
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Ecology Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Environmental Science Collection
Entomology Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Environmental Science Database
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
Meteorological & Geoastrophysical Abstracts - Academic
Technology Collection
Technology Research Database
Materials Science Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central
Genetics Abstracts
ProQuest Engineering Collection
Biotechnology Research Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Agricultural & Environmental Science Collection
AIDS and Cancer Research Abstracts
Materials Science Database
ProQuest Materials Science Collection
ProQuest Public Health
ProQuest Nursing & Allied Health Source
ProQuest SciTech Collection
Advanced Technologies & Aerospace Database
ProQuest Medical Library
Animal Behavior Abstracts
Materials Science & Engineering Collection
Immunology Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE




Agricultural Science Database
MEDLINE - Academic



Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
Medicine
Biology
DocumentTitleAlternate emm Types of Group A Streptococcal Isolates
EISSN 1932-6203
Editor de Lencastre, Herminia
Editor_xml – sequence: 1
  givenname: Herminia
  surname: de Lencastre
  fullname: de Lencastre, Herminia
EndPage e71558
ExternalDocumentID 1430787627
oai_doaj_org_article_0381cedbef2b4294a5dc966f3b346c4d
3066042231
A478215296
10_1371_journal_pone_0071558
23977078
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Greece
Aachen Germany
Germany
GeographicLocations_xml – name: Greece
– name: Aachen Germany
– name: Germany
GroupedDBID ---
123
29O
2WC
3V.
53G
5VS
7RV
7X2
7X7
7XC
88E
8AO
8C1
8CJ
8FE
8FG
8FH
8FI
8FJ
A8Z
AAFWJ
ABDBF
ABIVO
ABJCF
ABUWG
ACGFO
ACIHN
ACIWK
ACPRK
ADBBV
ADRAZ
AEAQA
AENEX
AFKRA
AFRAH
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
APEBS
ARAPS
ATCPS
BAWUL
BBNVY
BBORY
BCNDV
BENPR
BGLVJ
BHPHI
BKEYQ
BPHCQ
BVXVI
BWKFM
CCPQU
CGR
CS3
CUY
CVF
D1I
D1J
D1K
DIK
DU5
E3Z
EAP
EAS
EBD
ECM
EIF
EMOBN
ESTFP
ESX
EX3
F5P
FPL
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
IOV
IPNFZ
IPY
ISE
ISR
ITC
K6-
KB.
KQ8
L6V
LK5
LK8
M0K
M1P
M48
M7P
M7R
M7S
M~E
NAPCQ
NPM
O5R
O5S
OK1
P2P
P62
PATMY
PDBOC
PIMPY
PQQKQ
PROAC
PSQYO
PTHSS
PV9
PYCSY
RIG
RNS
RPM
RZL
SV3
TR2
UKHRP
WOQ
WOW
~02
~KM
AAYXX
AFPKN
CITATION
7QG
7QL
7QO
7SN
7SS
7T5
7TG
7TM
7U9
7XB
8FD
8FK
AZQEC
C1K
DWQXO
FR3
GNUQQ
H94
K9.
KL.
M7N
P64
PQEST
PQUKI
RC3
7X8
5PM
-
02
AAPBV
ABPTK
ADACO
BBAFP
KM
ID FETCH-LOGICAL-c692t-70d36825fb3ce126b7d825fb2dae424beeee4fdcab63e0badbddd0fd47418e2f3
IEDL.DBID RPM
ISSN 1932-6203
IngestDate Fri Nov 26 17:12:43 EST 2021
Tue Oct 22 15:14:36 EDT 2024
Tue Sep 17 21:10:41 EDT 2024
Fri Oct 25 01:04:20 EDT 2024
Sat Nov 09 15:11:13 EST 2024
Fri Feb 23 00:04:11 EST 2024
Tue Nov 12 22:38:15 EST 2024
Thu Aug 01 19:13:23 EDT 2024
Thu Aug 01 19:25:49 EDT 2024
Tue Aug 20 22:02:43 EDT 2024
Fri Aug 23 00:53:55 EDT 2024
Tue Oct 15 23:46:50 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
Creative Commons Attribution License
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c692t-70d36825fb3ce126b7d825fb2dae424beeee4fdcab63e0badbddd0fd47418e2f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interests: The authors have read the journal's policy and have the following conflicts: MvdL has received research grants from Wyeth/Pfizer and GSK and acts as a consultant for Wyeth/Pfizer, Sanofi-Aventis and GSK. RRR is currently an employee of Pfizer Pharmaceuticals. ING, GAS, AA-L, MP and AGT declare no competing interests. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Conceived and designed the experiments: GAS ING RRR MvdL. Performed the experiments: ING AA-L MP. Analyzed the data: MP AGT ANM. Contributed reagents/materials/analysis tools: GAS RRR MvdL. Wrote the paper: GAS ING AA-L MP AGT ANM RRR MvdL.
Current address: Pfizer Pharmaceuticals, Paris, France
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747210/
PMID 23977078
PQID 1430787627
PQPubID 1436336
PageCount e71558
ParticipantIDs plos_journals_1430787627
doaj_primary_oai_doaj_org_article_0381cedbef2b4294a5dc966f3b346c4d
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3747210
proquest_miscellaneous_1428271427
proquest_journals_1430787627
gale_infotracmisc_A478215296
gale_infotracacademiconefile_A478215296
gale_incontextgauss_ISR_A478215296
gale_incontextgauss_IOV_A478215296
gale_healthsolutions_A478215296
crossref_primary_10_1371_journal_pone_0071558
pubmed_primary_23977078
PublicationCentury 2000
PublicationDate 2013-08-19
PublicationDateYYYYMMDD 2013-08-19
PublicationDate_xml – month: 08
  year: 2013
  text: 2013-08-19
  day: 19
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: San Francisco
– name: San Francisco, USA
PublicationTitle PloS one
PublicationTitleAlternate PLoS One
PublicationYear 2013
Publisher Public Library of Science
Public Library of Science (PLoS)
Publisher_xml – name: Public Library of Science
– name: Public Library of Science (PLoS)
References 15855540 - Antimicrob Agents Chemother. 2005 May;49(5):2109-11
20206477 - Int J Antimicrob Agents. 2010 Jun;35(6):614-5
14461914 - J Immunol. 1962 Sep;89:307-13
18073148 - J Chemother. 2007 Oct;19(5):500-7
17806049 - Clin Infect Dis. 2007 Oct 1;45(7):853-62
21749758 - Emerg Infect Dis. 2011 Jun;17(6):983-9
16371871 - Pediatr Infect Dis J. 2005 Dec;24(12):1089-92
17806050 - Clin Infect Dis. 2007 Oct 1;45(7):863-5
2081237 - Epidemiology. 1990 Jan;1(1):43-6
8873386 - Vaccine. 1996 Jul;14(10):944-8
19158266 - J Clin Microbiol. 2009 Apr;47(4):1155-65
12624074 - J Clin Microbiol. 2003 Mar;41(3):1307-10
6166868 - Nature. 1981 Jul 30;292(5822):457-9
22998619 - BMC Microbiol. 2012;12:215
15328126 - Antimicrob Agents Chemother. 2004 Sep;48(9):3559-62
19395219 - Diagn Microbiol Infect Dis. 2009 Jul;64(3):295-9
10428916 - Antimicrob Agents Chemother. 1999 Aug;43(8):1935-40
19778763 - Lancet Infect Dis. 2009 Oct;9(10):611-6
22099088 - Emerg Infect Dis. 2011 Nov;17(11):2010-7
22908153 - Antimicrob Agents Chemother. 2012 Nov;56(11):5661-6
2422314 - J Exp Med. 1986 May 1;163(5):1191-202
8815115 - J Clin Microbiol. 1996 Apr;34(4):953-8
9987154 - Vaccine. 1999 Jan;17(2):193-200
1784271 - Med Microbiol Immunol. 1991;180(4):213-27
12791853 - J Clin Microbiol. 2003 Jun;41(6):2385-90
20118164 - J Antimicrob Chemother. 2010 Apr;65(4):634-43
15616836 - Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):68-70
21920403 - Vaccine. 2011 Oct 26;29(46):8175-8
18813950 - Eur J Pediatr. 2009 Jun;168(6):679-83
19480575 - Clin Infect Dis. 2009 Jul 1;49(1):78-84
11442342 - Microb Drug Resist. 2001 Summer;7(2):165-70
17638193 - Clin Infect Dis. 2007 Aug 15;45(4):450-8
16163629 - Clin Infect Dis. 2005 Oct 15;41(8):1114-22
16849733 - J Med Microbiol. 2006 Aug;55(Pt 8):1115-23
12435707 - Antimicrob Agents Chemother. 2002 Dec;46(12):3987-90
22932671 - Emerg Infect Dis. 2012 Sep;18(9):1515-8
19046174 - Clin Microbiol Infect. 2008 Dec;14(12):1152-9
15578402 - Clin Infect Dis. 2004 Dec 15;39(12):1794-801
12679262 - Lancet Infect Dis. 2003 Apr;3(4):191-200
2579187 - J Exp Med. 1985 Mar 1;161(3):623-8
18077121 - Diagn Microbiol Infect Dis. 2008 Apr;60(4):393-8
15361727 - Pediatr Infect Dis J. 2004 Sep;23(9):857-65
11895984 - Infect Immun. 2002 Apr;70(4):2171-7
16377695 - Antimicrob Agents Chemother. 2006 Jan;50(1):256-61
PR Shea (ref35) 2011; 17
CM Brandt (ref21) 2001; 7
G Dicuonzo (ref37) 2002; 46
A Podbielski (ref22) 1991; 180
L Van Heirstraeten (ref27) 2012; 18
ref1
J Darenberg (ref36) 2007; 45
EH Beachey (ref3) 1981; 292
C Silva-Costa (ref28) 2012; 56
MC Hu (ref11) 2002; 70
JB Dale (ref5) 1986; 163
IN Grivea (ref17) 2006; 50
A Rivera (ref32) 2006; 55
AG Michos (ref29) 2009; 64
DA Kafetzis (ref41) 2005; 24
JB Dale (ref45) 2011; 29
B Luca-Harari (ref43) 2009; 47
KJ Rothman (ref23) 1990; 1
P Jaggi (ref40) 2009; 168
C Zampaloni (ref31) 2003; 41
S Albertí (ref30) 2003; 41
B Beall (ref6) 1996; 34
AL Bisno (ref7) 2003; 3
P Jaggi (ref39) 2005; 24
E Malli (ref18) 2010; 35
A Safar (ref44) 2011; 17
C Silva-Costa (ref14) 2005; 49
C Silva-Costa (ref25) 2008; 14
C Ardanuy (ref26) 2010; 65
KF Jones (ref4) 1985; 161
GA Syrogiannopoulos (ref19) 2004; 23
RE O'Loughlin (ref42) 2007; 45
JB Dale (ref10) 1999; 17
JB Dale (ref9) 1996; 14
RR Tanz (ref34) 2004; 39
GL Daikos (ref24) 2008; 60
ST Shulman (ref33) 2009; 49
A Mazzariol (ref15) 2007; 19
V Rubio-López (ref16) 2012; 12
AC Steer (ref38) 2009; 9
R Cohen-Poradosu (ref8) 2007; 45
SA McNeil (ref12) 2005; 41
E Giovanetti (ref20) 1999; 43
E Bingen (ref13) 2004; 48
RC Lancefield (ref2) 1962; 89
References_xml – ident: ref1
– volume: 34
  start-page: 953
  year: 1996
  ident: ref6
  article-title: Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.34.4.953-958.1996
  contributor:
    fullname: B Beall
– volume: 3
  start-page: 191
  year: 2003
  ident: ref7
  article-title: Molecular basis of group A streptococcal virulence
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(03)00576-0
  contributor:
    fullname: AL Bisno
– volume: 60
  start-page: 393
  year: 2008
  ident: ref24
  article-title: Evolution of macrolide resistance in Streptococcus pneumoniae clinical isolates in the prevaccine era
  publication-title: Diagn Microbiol Infect Dis
  doi: 10.1016/j.diagmicrobio.2007.10.020
  contributor:
    fullname: GL Daikos
– volume: 39
  start-page: 1794
  year: 2004
  ident: ref34
  article-title: Community-based surveillance in the United States of macrolide-resistant pediatric pharyngeal group A streptococci during 3 respiratory disease seasons
  publication-title: Clin Infect Dis
  doi: 10.1086/426025
  contributor:
    fullname: RR Tanz
– volume: 23
  start-page: 857
  year: 2004
  ident: ref19
  article-title: Two dosages of clarithromycin for five days, amoxicillin/clavulanate for five days or penicillin V for ten days in acute group A streptococcal tonsillopharyngitis
  publication-title: Pediatr Infect Dis J
  doi: 10.1097/01.inf.0000138080.74674.a2
  contributor:
    fullname: GA Syrogiannopoulos
– volume: 24
  start-page: 1089
  year: 2005
  ident: ref39
  article-title: Age influences the emm type distribution of pediatric group A streptococcal pharyngeal isolates
  publication-title: Pediatr Infect Dis J
  doi: 10.1097/01.inf.0000190023.89759.96
  contributor:
    fullname: P Jaggi
– volume: 41
  start-page: 2385
  year: 2003
  ident: ref30
  article-title: Survey of emm gene sequences from pharyngeal Streptococcus pyogenes isolates collected in Spain and their relationship with erythromycin susceptibility
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.41.6.2385-2390.2003
  contributor:
    fullname: S Albertí
– volume: 17
  start-page: 2010
  year: 2011
  ident: ref35
  article-title: Group A Streptococcus emm gene types in pharyngeal isolates, Ontario, Canada, 2002–2010
  publication-title: Emerg Infect Dis
  contributor:
    fullname: PR Shea
– volume: 29
  start-page: 8175
  year: 2011
  ident: ref45
  article-title: New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2011.09.005
  contributor:
    fullname: JB Dale
– volume: 163
  start-page: 1191
  year: 1986
  ident: ref5
  article-title: Localization of protective epitopes of the amino terminus of type 5 streptococcal M protein
  publication-title: J Exp Med
  doi: 10.1084/jem.163.5.1191
  contributor:
    fullname: JB Dale
– volume: 24
  start-page: 68
  year: 2005
  ident: ref41
  article-title: Incidence and clinical profile of acute rheumatic fever in Greece
  publication-title: Eur J Clin Microbiol Infect Dis
  doi: 10.1007/s10096-004-1274-6
  contributor:
    fullname: DA Kafetzis
– volume: 17
  start-page: 193
  year: 1999
  ident: ref10
  article-title: Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments
  publication-title: Vaccine
  doi: 10.1016/S0264-410X(98)00150-9
  contributor:
    fullname: JB Dale
– volume: 46
  start-page: 3987
  year: 2002
  ident: ref37
  article-title: Erythromycin-resistant pharyngeal isolates of Streptococcus pyogenes recovered in Italy
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.46.12.3987-3990.2002
  contributor:
    fullname: G Dicuonzo
– volume: 47
  start-page: 1155
  year: 2009
  ident: ref43
  article-title: Clinical and microbiological characteristics of severe Streptococcus pyogenes disease in Europe
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.02155-08
  contributor:
    fullname: B Luca-Harari
– volume: 14
  start-page: 944
  year: 1996
  ident: ref9
  article-title: Recombinant, octavalent group A streptococcal M protein vaccine
  publication-title: Vaccine
  doi: 10.1016/0264-410X(96)00050-3
  contributor:
    fullname: JB Dale
– volume: 45
  start-page: 863
  year: 2007
  ident: ref8
  article-title: Group A streptococcus epidemiology and vaccine implications
  publication-title: Clin Infect Dis
  doi: 10.1086/521263
  contributor:
    fullname: R Cohen-Poradosu
– volume: 19
  start-page: 500
  year: 2007
  ident: ref15
  article-title: Susceptibilities of Streptococcus pyogenes and Streptococcus pneumoniae to macrolides and telithromycin: data from an Italian multicenter study
  publication-title: J Chemother
  doi: 10.1179/joc.2007.19.5.500
  contributor:
    fullname: A Mazzariol
– volume: 64
  start-page: 295
  year: 2009
  ident: ref29
  article-title: Macrolide resistance in Streptococcus pyogenes: prevalence, resistance determinants, and emm types
  publication-title: Diagn Microbiol Infect Dis
  doi: 10.1016/j.diagmicrobio.2009.03.004
  contributor:
    fullname: AG Michos
– volume: 65
  start-page: 634
  year: 2010
  ident: ref26
  article-title: Molecular characterization of macrolide- and multidrug-resistant Streptococcus pyogenes isolated from adult patients in Barcelona, Spain (1993–2008)
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkq006
  contributor:
    fullname: C Ardanuy
– volume: 56
  start-page: 5661
  year: 2012
  ident: ref28
  article-title: Differences between macrolide-resistant and -susceptible Streptococcus pyogenes: importance of clonal properties in addition to antibiotic consumption
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01133-12
  contributor:
    fullname: C Silva-Costa
– volume: 14
  start-page: 1152
  year: 2008
  ident: ref25
  article-title: Decrease in macrolide resistance and clonal instability among Streptococcus pyogenes in Portugal
  publication-title: Clin Microbiol Infect
  doi: 10.1111/j.1469-0691.2008.02104.x
  contributor:
    fullname: C Silva-Costa
– volume: 55
  start-page: 1115
  year: 2006
  ident: ref32
  article-title: Superantigen gene profile, emm type and antibiotic resistance genes among group A streptococcal isolates from Barcelona, Spain
  publication-title: J Med Microbiol
  doi: 10.1099/jmm.0.46481-0
  contributor:
    fullname: A Rivera
– volume: 70
  start-page: 2171
  year: 2002
  ident: ref11
  article-title: Immunogenicity of a 26-valent group A streptococcal vaccine
  publication-title: Infect Immun
  doi: 10.1128/IAI.70.4.2171-2177.2002
  contributor:
    fullname: MC Hu
– volume: 41
  start-page: 1114
  year: 2005
  ident: ref12
  article-title: Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers
  publication-title: Clin Infect Dis
  doi: 10.1086/444458
  contributor:
    fullname: SA McNeil
– volume: 41
  start-page: 1307
  year: 2003
  ident: ref31
  article-title: emm Gene distribution among erythromycin-resistant and -susceptible Italian isolates of Streptococcus pyogenes
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.41.3.1307-1310.2003
  contributor:
    fullname: C Zampaloni
– volume: 9
  start-page: 611
  year: 2009
  ident: ref38
  article-title: Global emm type distribution of group A streptococci: systematic review and implications for vaccine development
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(09)70178-1
  contributor:
    fullname: AC Steer
– volume: 35
  start-page: 614
  year: 2010
  ident: ref18
  article-title: Macrolide-resistant Streptococcus pyogenes in Central Greece: prevalence; mechanism and molecular identification
  publication-title: Int J Antimicrob Agents
  doi: 10.1016/j.ijantimicag.2010.01.025
  contributor:
    fullname: E Malli
– volume: 161
  start-page: 623
  year: 1985
  ident: ref4
  article-title: Location of variable and conserved epitopes among the multiple serotypes of streptococcal M protein
  publication-title: J Exp Med
  doi: 10.1084/jem.161.3.623
  contributor:
    fullname: KF Jones
– volume: 45
  start-page: 853
  year: 2007
  ident: ref42
  article-title: The epidemiology of invasive group A streptococcal infection and possible vaccine implications: United States, 2000–2004
  publication-title: Clin Infect Dis
  doi: 10.1086/521264
  contributor:
    fullname: RE O'Loughlin
– volume: 292
  start-page: 457
  year: 1981
  ident: ref3
  article-title: Type-specific protective immunity evoked by synthetic peptide of Streptococcus pyogenes M protein
  publication-title: Nature (London)
  doi: 10.1038/292457a0
  contributor:
    fullname: EH Beachey
– volume: 48
  start-page: 3559
  year: 2004
  ident: ref13
  article-title: Emergence of macrolide-resistant Streptococcus pyogenes strains in French children
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.48.9.3559-3562.2004
  contributor:
    fullname: E Bingen
– volume: 50
  start-page: 256
  year: 2006
  ident: ref17
  article-title: Resistance to erythromycin and telithromycin in Streptococcus pyogenes isolates obtained between 1999 and 2002 from Greek children with tonsillopharyngitis: phenotypic and genotypic analysis
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.50.1.256-261.2006
  contributor:
    fullname: IN Grivea
– volume: 49
  start-page: 78
  year: 2009
  ident: ref33
  article-title: Seven-year surveillance of North American pediatric group A streptococcal pharyngitis isolates
  publication-title: Clin Infect Dis
  doi: 10.1086/599344
  contributor:
    fullname: ST Shulman
– volume: 168
  start-page: 679
  year: 2009
  ident: ref40
  article-title: Age-associated differences in prevalence of group A streptococcal type-specific M antibodies in children
  publication-title: Eur J Pediatr
  doi: 10.1007/s00431-008-0819-6
  contributor:
    fullname: P Jaggi
– volume: 49
  start-page: 2109
  year: 2005
  ident: ref14
  article-title: Rapid inversion of the prevalences of macrolide resistance phenotypes paralleled by a diversification of T and emm types among Streptococcus pyogenes in Portugal
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.49.5.2109-2111.2005
  contributor:
    fullname: C Silva-Costa
– volume: 18
  start-page: 1515
  year: 2012
  ident: ref27
  article-title: Antimicrobial drug use and macrolide-resistant Streptococcus pyogenes, Belgium
  publication-title: Emerg Infect Dis
  doi: 10.3201/eid1809.120049
  contributor:
    fullname: L Van Heirstraeten
– volume: 45
  start-page: 450
  year: 2007
  ident: ref36
  article-title: Molecular and clinical characteristics of invasive group A streptococcal infection in Sweden
  publication-title: Clin Infect Dis
  doi: 10.1086/519936
  contributor:
    fullname: J Darenberg
– volume: 89
  start-page: 307
  year: 1962
  ident: ref2
  article-title: Current knowledge of type-specific M antigens of group A streptococci
  publication-title: J Immunol
  doi: 10.4049/jimmunol.89.3.307
  contributor:
    fullname: RC Lancefield
– volume: 7
  start-page: 165
  year: 2001
  ident: ref21
  article-title: Macrolide resistance in Streptococcus pyogenes isolates from throat infections in the region of Aachen, Germany
  publication-title: Microb Drug Resist
  doi: 10.1089/10766290152045039
  contributor:
    fullname: CM Brandt
– volume: 180
  start-page: 213
  year: 1991
  ident: ref22
  article-title: Application of the polymerase chain reaction to study the M protein (-like) gene family in beta-hemolytic streptococci
  publication-title: Med Microbiol Immunol
  doi: 10.1007/BF00215250
  contributor:
    fullname: A Podbielski
– volume: 17
  start-page: 983
  year: 2011
  ident: ref44
  article-title: Invasive group A streptococcal infection and vaccine implications, Auckland, New Zealand
  publication-title: Emerg Infect Dis
  doi: 10.3201/eid/1706.100804
  contributor:
    fullname: A Safar
– volume: 12
  start-page: 215
  year: 2012
  ident: ref16
  article-title: Molecular epidemiology, antimicrobial susceptibilities and resistance mechanisms of Streptococcus pyogenes isolates resistant to erythromycin and tetracycline in Spain (1994–2006)
  publication-title: BMC Microbiol
  doi: 10.1186/1471-2180-12-215
  contributor:
    fullname: V Rubio-López
– volume: 43
  start-page: 1935
  year: 1999
  ident: ref20
  article-title: Phenotypes and genotypes of erythromycin-resistant Streptococcus pyogenes strains in Italy and heterogeneity of inducibly resistant strains
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.43.8.1935
  contributor:
    fullname: E Giovanetti
– volume: 1
  start-page: 43
  year: 1990
  ident: ref23
  article-title: No adjustments are needed for multiple comparisons
  publication-title: Epidemiology
  doi: 10.1097/00001648-199001000-00010
  contributor:
    fullname: KJ Rothman
SSID ssj0053866
Score 2.2900488
Snippet An experimental 26-valent M protein Group A streptococcal (GAS) vaccine has entered clinical studies. Pharyngeal GAS emm type surveillances in different areas...
Background An experimental 26-valent M protein Group A streptococcal (GAS) vaccine has entered clinical studies. Pharyngeal GAS emm type surveillances in...
BACKGROUNDAn experimental 26-valent M protein Group A streptococcal (GAS) vaccine has entered clinical studies. Pharyngeal GAS emm type surveillances in...
BACKGROUND: An experimental 26-valent M protein Group A streptococcal (GAS) vaccine has entered clinical studies. Pharyngeal GAS emm type surveillances in...
Background An experimental 26-valent M protein Group A streptococcal (GAS) vaccine has entered clinical studies. Pharyngeal GAS emm type surveillances in...
SourceID plos
doaj
pubmedcentral
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage e71558
SubjectTerms Adolescent
Analysis
Antibiotics
Antigens, Bacterial - immunology
Bacterial infections
Bacterial Outer Membrane Proteins - immunology
Biology
Carrier Proteins - immunology
Child
Child, Preschool
Children
Drug Resistance, Bacterial - drug effects
Epidemiology
Genes, Bacterial - genetics
Genotype
Greece - epidemiology
Health sciences
Hospitals
Humans
Immunoglobulins
Infant
Infant, Newborn
Infections
Infectious diseases
Laboratories
M protein
Macrolides - pharmacology
Medical research
Medicine
Microbial drug resistance
Microbial Sensitivity Tests
Microbiology
Pediatrics
Pharyngitis
Pharyngitis - epidemiology
Pharyngitis - immunology
Pharyngitis - microbiology
Pharyngitis - prevention & control
Pharynx
Pharynx - drug effects
Pharynx - microbiology
Pharynx - pathology
Phenotype
Population Surveillance
Proteins
Rheumatic fever
Seasonal variations
Sore throat
Statistical analysis
Streptococcal Vaccines - immunology
Streptococcus infections
Streptococcus pyogenes
Streptococcus pyogenes - classification
Streptococcus pyogenes - drug effects
Streptococcus pyogenes - genetics
Streptococcus pyogenes - isolation & purification
Surveillance
Typing
Vaccines
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbQnrggyquBAgYhAQfT3dhrJ8cFURUOIFEKvUV-0pVoEm12kfrvmXGcqEGV4MAeIiWejZJ5eSYef0PICy5NKHLPmVShYEJwxco5d8wqbmFGgBDFxmqLT_L4VHw8W55dafWFNWE9PHDPuENcybLeGR9yA75T6KWzEKIHbriQVrjofeflkEz1PhisWMq0UY6rxWGSy5u2qT2CZcMkWkwmoojXP3rlWfuz6a4LOf-snLwyFR3dJrdSDElX_bPvkRu-vkP2kpV29FWCkn59l9QnCNDELkGdabfb_PLYYwiIaBOov7ig-AG2w5N26NhB48couqK4iaTdNuAvQYq0PdebS2xttO7oGtQVI1S6run3HmiBYvmO9ffI6dH7r--OWeqwwKws8y1Tc8cl5IjBcOsXuTTKxbPcaS9yYTz8RHBWG8n93GhnnHPz4ARi3vg88PtkVgNP9wnVwumy0HC11OAHlkaBr1iqsjTGeXAjGWEDu6u2B9Ko4mqaggSk51uF4qmSeDLyFmUy0iIMdrwAylEl5aj-phwZeYoSrfo9paMxVysBgdECl5wz8jxSIBRGjbU2P_Su66oPn7_9A9HJlwnRy0QUGtANq9P-BngnhNiaUB5MKMGg7WR4H_Vv4EoH2Rk4Ypy1FPxz0Mnrh5-Nw3hTrJ-rfbNDGkitFRyB5kGvwiNnc8wB4A4ZURPlnrB-OlKvzyMSOYdkFKzv4f-Q1SNyM4-tRgq2KA_IbLvZ-ccQ8G3Nk2jbvwGCLVbE
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjR1db9Mw0IIiIV7QNj5WNsAgJODBLLFdu3lCBTFtSHyIMuieovgjWyWWlKZF4t9z57iBoAnRh0qJr1F63-c73xHyRChTjrkXTOlyzKQUmmWJcMxqYcEigItiQ7XFe3V0It_ORrO44dbEssqNTgyK2tUW98gPwK6DNQPR1S8X3xlOjcLsahyhcZVcS3misKRLz7qAC2RZqXhcTuj0IFLnxaKuPLbMBlM67pmj0LW_082Dxbe6uczx_Lt-8g-DdLhFbkZPkk5a0m-TK77aIdffxVz5DtmOYtvQZ7G39PNbpJpixyZ2CvxNp-vlD49DhwCI1iX1FxcUw9IGL7oRHjTsTtEJxfz1YlWDAgWy0o_nxfInzjqaN_QY-BddVjqv6Ne28wLFeh7rb5OTwzefXx-xOHKBWZXxFdOJEwqCxtII61OujHbhirvCSy6Nh48snS2MEj4xhTPOuaR0EpvgeF6KO2RQAXp3CS2kK7JxAXezAhTDyGhQHiOdZcY4D3plSNgG8_mi7ayRh_SahoikRWGOlMojpYbkFZKng8W-2OFGvTzLo5jlmPe03hlfcgOWVhYjZyGgK4URUlnphuQhEjdvD5l20p1PJHhKKeagh-RxgMDeGBUW35wV66bJjz98-Q-g6ace0NMIVNbAJraIBx7gP2HPrR7kfg8SJNz2lneRFTdYafLfsgC_3LDn5cuPumV8KBbUVb5eIwzE2hq-AeZuy80dZjkGBfCEIdE9Pu-hvr9Szc9Da3IB0SlPk3v_fq09coOHqSJjlmb7ZLBarv198O1W5kEQ4F8DZE_J
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access(OpenAccess)
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9NAEF6VcOGCKK8GCiwICThsZe9uvPEBoYCoWg6ACIFysvblNlJrBztB9N8zs34IoyA1h0j2jlfK7Dwz428IeS4Sk0-5FyxR-ZRJKRRLI-GYVcKCR4AQxYZui4_J0UJ-OJmc7JBuZmvLwHpraofzpBbV-cHvn5dvQOFfh6kNKu4eOliVhUcobHCR02vkOpeQq2Mzn-zrCqDdoXqJUQtLeCTal-n-t8vAWQVM_95yj1bnZb0tLP23u_Ivd3V4i9xs40w6awRjl-z44jbZbTW5pi9buOlXd0gxRxAn9gNEns431S-Pc4iAiJY59RcXFDPVGi_6qR40_GFFZxRL2qt1CTYVTpp-PtPVJY4_Wtb0GEQao1i6LOj3BoyBYouP9XfJ4vD913dHrJ3CwGyS8jVTkRMJ5JG5EdbHPDHKhSvutJdcGg8fmTurTSJ8ZLQzzrkodxJxcTzPxT0yKoCne4Rq6XQ61XA31WArJkaBPZmoNDXGeTA1Y8I6dmerBmwjCxU3BUlKw7cMjydrj2dM3uKZ9LQIlR1ulNVp1mpehqVQ653xOTfgfKWeOAs5Xi6MkImVbkye4IlmzXunvcJnMwnBU4xl6TF5FigQLqPAfpxTvanr7PjTtysQzb8MiF60RHkJsmF1-w4E_CaE4RpQ7g8oQentYHkP5a_jSg0ZHBhr9GwKnuxkcvvy034ZN8Ueu8KXG6SB9FvBN9Dcb0S45yzHPAF2GBM1EO4B64crxfIsoJULSFh5HD24Cn8ekhs8jBuZsjjdJ6N1tfGPIOhbm8dBj_8AlKtWQg
  priority: 102
  providerName: Scholars Portal
Title Seven-year surveillance of emm types of pediatric Group A streptococcal pharyngitis isolates in Western Greece
URI https://www.ncbi.nlm.nih.gov/pubmed/23977078
https://www.proquest.com/docview/1430787627
https://search.proquest.com/docview/1428271427
https://pubmed.ncbi.nlm.nih.gov/PMC3747210
https://doaj.org/article/0381cedbef2b4294a5dc966f3b346c4d
http://dx.doi.org/10.1371/journal.pone.0071558
Volume 8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF61QSAuiIZHAyUsCAk4OA_vxmsf0yihRUqJGgrpyfI-3EZq7ChOkHrhtzOzfqhGPSByWMnecZTsvL2z3xDygXky9l3DHE_EvsM5E07QY9pRginwCBCiKFttceadXPCvi8FijwzKszC2aF_JZSe5WXWS5bWtrVyvVLesE-vOpiMGMTAePdkn-yCgZYqem19QYM8rzsgx0e8WLOms08QgTjb4T-zR52Lg08PmanfckUXtr2xzY32TZvcFnn_XT95xSJOn5EkRSdJh_osPyJ5JmuRh3lvytkkeTYtd8yY5KBQ4o58KlOnPz0gyR-wm5xIknc53m18G2w8BEU1jalYriglqhhdVMw9q31PRIcWd7PU2BVMKDKaz62hzi12Plhk9BUnG4JUuE_ozx2CgWNmjzHNyMRl_H504RfMFR3mBu3VETzMP0sdYMmX6rieFtleujgx3uTTw4bFWkfSY6clIS611L9Yc4XCMG7MXpJHAmh8SGnEdBX4Ed4MITMRACjAjAxEEUmoDDGwRp-RBuM4xNkK70SYgN8kXM0T2hQX7WuQYGVXRIkK2vZFursJCTkLcAVVGSxO7EnwujwZaQWoXM8m4p7hukbfI5jA_blrpeTjkEDP1cTe6Rd5bCkTJSLAM5yraZVl4-u3HPxDNz2tEHwuiOAWBUVFx9AH-E6Jv1SiPapSg66o2fYhCWa5KBokb2Gh0aAKeLAX1_ul31TR-KZbWJSbdIQ1k3QJGoHmZy3W1sqWWtIioSXxt6eszoLMWpLzQ0Vf__eRr8ti1rUd8px8ckcZ2szNvIADcyjao_ULA6I_6OE6-tMmD4_HZ7LxtX6nAOOU-jr_HbWsc_gDc4mLW
link.rule.ids 230,315,730,783,787,867,888,2109,2228,12068,12235,12777,21400,24330,27936,27937,31731,31732,33278,33279,33385,33386,33756,33757,43322,43591,43612,43817,53804,53806,74073,74342,74363,74630
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjR1db9Mw0IJOAl4QGx_rGMwgJODBrI3duHlCHdrUwlamdYPxZPkrW6UtKU2LxL_nLnEDQROiD5USX6P0vs93viPkFY9N2o88Z7FM-0wILlnS4Y5ZyS1YBHBRbFltMY6HZ-Ljee88bLgVoaxypRNLRe1yi3vku2DXwZqB6Mr3s-8Mp0ZhdjWM0LhN1rBVFQRfa3v74-OTlS4GaY7jcGCOy-5uoM-7WZ55bJoNxrTfMEhl3_5aO7dmV3lxk-v5dwXlHybp4AG5H3xJOqiIv05u-WyD3DkK2fINsh4Et6BvQnfptw9JNsGeTewbcDidLOc_PI4dAiCap9RfX1MMTAu8qId40HJ_ig4oZrBnixxUKBCWHl_q-U-cdjQt6Ag4GJ1WOs3o16r3AsWKHusfkbOD_dMPQxaGLjAbJ9GCyY7jMYSNqeHWd6PYSFdeRU57EQnj4SNSZ7WJue8Y7YxzrpM6gW1wfJTyx6SVAXo3CdXC6aSv4W6iQTX0jAT10ZNJYozzoFnahK0wr2ZVbw1VJtgkxCQVChVSSgVKtckekqeGxc7Y5Y18fqGCoCnMfFrvjE8jA7ZW6J6zENKl3HARW-HaZAeJq6pjprV8q4EAX6mLWeg2eVlCYHeMDMtvLvSyKNTo85f_AJqcNIBeB6A0BzaxOhx5gP-EXbcakNsNSJBx21jeRFZcYaVQv6UBfrliz5uXX9TL-FAsqct8vkQYiLYlfAPMk4qba8xGGBbAE9pENvi8gfrmSja9LJuTc4hPo25n69-vtUPuDk-PDtXhaPzpKbkXlTNG-qybbJPWYr70z8DTW5jnQZx_AZNqVB8
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjR3LbtNAcAVBqrigtjwaWuiCkICDSeLdeO0TCoWo4VEqQks5WftsI1E7xAkSf8_MemMwqhA5WLJ3YtnzHs_sDCFPWKJcGlsWJcKlEedMRFmfmUgLpsEigIuifbXFUXJ4wt-eDc9C_VMVyirXOtEralNq_EbeA7sO1gxEV_RcKIs4fj1-Of8e4QQpzLSGcRrXyQ2wihynGaQHTbkHyHWShK1zTAx6gVIv5mVhsX02mNW0ZZp8B_9GT3fm38rqKif071rKP4zTeJPcCl4lHdVssEWu2WKbbHwIefNtshVEuKLPQp_p57dJMcXuTdFX4HU6XS1-WBxABEC0dNReXlIMUSs8acZ5UP-lio4o5rLnyxKUKZCYHl_IxU-cezSr6AR4Gd1XOivol7oLA8XaHm3vkJPxm88Hh1EYvxDpJIuXkegblkAA6RTTdhAnShh_FhtpecyVhR93RkuVMNtX0ihjTN8Zjg1xbOzYXdIpAL07hEpuZJZKuJpJUBJDJUCRDEWWKWUs6JguidaYz-d1l43cp9oERCc1CnOkVB4o1SWvkDwNLPbI9hfKxXkeRC7HHKi2RlkXK7C6XA6NhuDOMcV4ornpkn0kbl5vOG0kPR9x8JoGmI_uksceAvtkFMhx53JVVfnk4-l_AE0_tYCeBiBXAptoGTY_wDth_60W5F4LEqRdt5Z3kBXXWKny33IB_1yz59XLj5plvCkW1xW2XCEMxN0CjgBzr-bmBrMxBghwhy4RLT5vob69UswufJtyBpFqPOjf__dj7ZMNkOP8_eTo3S65GfthI2k0yPZIZ7lY2Qfg8i3VQy_LvwBxZlaz
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Seven-Year+Surveillance+of+emm+Types+of+Pediatric+Group+A+Streptococcal+Pharyngitis+Isolates+in+Western+Greece&rft.jtitle=PloS+one&rft.au=Syrogiannopoulos%2C+George+A&rft.au=Grivea%2C+Ioanna+N&rft.au=Al-Lahham%2C+Adnan&rft.au=Panagiotou%2C+Maria&rft.date=2013-08-19&rft.pub=Public+Library+of+Science&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=8&rft.issue=8&rft.spage=e71558&rft_id=info:doi/10.1371%2Fjournal.pone.0071558&rft.externalDBID=ISR&rft.externalDocID=A478215296
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon